Lymphoma Follow-up

Lymphoma Clinical Trial

Official title:

Lymphoma Follow-up Protocol

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00744120
• Other study ID #: AG0108
• Status: Completed
• Phase: N/A
• First received: August 28, 2008
• Last updated: December 19, 2013
• Start date: October 2003
• Est. completion date: September 2013

Study information

• Verified date: December 2013
• Source: National Institutes of Health Clinical Center (CC)
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Observational

Clinical Trial Summary

This follow-up protocol is designed to evaluate participants who have previously been lymphoma patients treated on approved clinical studies of the National Institutes of Health.

Description:

The intent of this protocol is to accrue up to 800 volunteers who are interested in participating in NIA research studies as part of follow-up for previous cancer treatment at NIH. Participants will be asked to answer questions regarding their general health status, diagnoses, and admissions to hospital, and to provide possible documentation. They may be asked to come to the NIA Clinical Research Unit at Harbor Hospital to participate in a follow-up evaluation. They will have the opportunity to obtain additional information about studies in which they may wish to participate and to discuss eligibility issues with NIA staff members. Any identified clinical problems in need of care will also be discussed. Volunteers may be referred, with their permission, to their private medical doctor for follow-up. They may be re-evaluated within a year for further follow-up.

The follow-up evaluation may include history and physical, blood and urine tests, questionnaire, MRI or CT.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 51
• Est. completion date: September 2013
• Est. primary completion date: September 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 21 Years and older

Eligibility

Inclusion Criteria:

• Previously treated on an approved NCI/NIH protocols

• Willing and able to provide informed consent for current NIA protocol

• Rare, unusual, interesting or unknown condition that requires diagnosis

Exclusion Criteria:

• Does not meet the criteria of any previously-approved NIH Protocol.

Study Design

Observational Model: Cohort, Time Perspective: Retrospective

Related Conditions & MeSH terms

• Lymphoma

Locations

Country	Name	City	State
United States	NIA Clinical Research Unit	Baltimore	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
National Institute on Aging (NIA)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Long-term survival following treatment for lymphoma		Annually	No
Secondary	Long-term toxicity possibly attributable to lymphoma or treatment for lymphoma		Annually	No